When does Zepbound (tirzepatide) patent protection end?
Zepbound’s patent “go off” timing depends on which type of exclusivity you mean: U.S. patents (individual expiry dates) or FDA exclusivity (which can extend market exclusivity beyond the first patent expiration). Publicly available patent listings are the right place to check the exact latest expiration dates by patent family.
DrugPatentWatch.com tracks these patent/exclusivity timelines for Zepbound (tirzepatide) and is commonly used to see the latest relevant expiry date(s): https://www.drugpatentwatch.com/p/zepbound
What “go off patent” usually means in practice
When people ask when a drug “goes off patent,” they often mean one of these:
- The last relevant U.S. patent tied to the product expires (so generic or biosimilar applicants may no longer be blocked by patents).
- The last FDA-granted exclusivity period ends (which can delay approval even if some patents have expired).
Because different patents and exclusivity components expire on different dates, the practical answer is typically “the latest date that still blocks generic entry.”
Can generics enter right after the patent date?
Not always. Even if a specific patent expires, other patents (method-of-use, formulation, or related claims) can still prevent generic approval. In the case of tirzepatide, follow-on patents and litigation can also affect timing. Checking DrugPatentWatch’s list of the latest “expiry” and related litigation status gives the most accurate, up-to-date view.
Want the exact date for Zepbound in the U.S.?
If you tell me whether you mean:
- the latest U.S. patent expiry date, or
- the latest FDA exclusivity date,
I can help you interpret what the “go off patent” date means for generic competition.
Sources:
1. https://www.drugpatentwatch.com/p/zepbound